about
Chemotherapy with Camptothecin compounds for metastatic colorectal cancerSubstrate specificity of tyrosyl-DNA phosphodiesterase I (Tdp1)Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancerCompartmentalized accumulation of cAMP near complexes of multidrug resistance protein 4 (MRP4) and cystic fibrosis transmembrane conductance regulator (CFTR) contributes to drug-induced diarrhea.Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme53BP1 is associated with replication protein A and is required for RPA2 hyperphosphorylation following DNA damageInvestigating the correlations among the chemical structures, bioactivity profiles and molecular targets of small moleculesIdentification of repurposed small molecule drugs for chordoma therapy.3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells.Design and synthesis of fluorescent substrates for human tyrosyl-DNA phosphodiesterase I.DOSY NMR and MALDI-TOF evidence of covalent binding the DNA duplex by trimethylammonium salts of topotecan upon near UV irradiation.Phase I dosage finding and pharmacokinetic study of intravenous topotecan and oral erlotinib in adults with refractory solid tumors.Optimization of liposomal topotecan for use in treating neuroblastoma.A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group studyA novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agentsA High Throughput Assay for Discovery of Bacterial β-Glucuronidase Inhibitors.A convergent synthetic platform for single-nanoparticle combination cancer therapy: ratiometric loading and controlled release of cisplatin, doxorubicin, and camptothecinPhosphorylation of BLM, dissociation from topoisomerase IIIalpha, and colocalization with gamma-H2AX after topoisomerase I-induced replication damage.Potential repurposing of known drugs as potent bacterial β-glucuronidase inhibitors.Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.Perspectives on biologically active camptothecin derivatives.Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.B-ring-aryl substituted luotonin A analogues with a new binding mode to the topoisomerase 1-DNA complex show enhanced cytotoxic activity.IT-141, a Polymer Micelle Encapsulating SN-38, Induces Tumor Regression in Multiple Colorectal Cancer Models.Functional-segregated coumarin-containing telodendrimer nanocarriers for efficient delivery of SN-38 for colon cancer treatment.Camptothecins in clinical development.Discovery of novel immunostimulants by dendritic-cell-based functional screening.Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China.Control of Mycosphaerella graminicola on wheat seedlings by medical drugs known to modulate the activity of ATP-binding cassette transportersPrevalence of topoisomerase I genetic mutations and UGT1A1 polymorphisms associated with irinotecan in individuals of Asian descentHuman cells enter mitosis with damaged DNA after treatment with pharmacological concentrations of genotoxic agents.Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutationsRecql5 plays an important role in DNA replication and cell survival after camptothecin treatment.Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11).Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
P2860
Q24242475-44773A8B-CEC1-47D4-8F5A-8031C0E39278Q24299565-16F74CE7-7A41-4F83-ACAE-C882D232E519Q24299998-E5BB0589-AB5F-44E2-A499-6E6F58BF8110Q24318465-27E6BAD3-EE58-4E6B-A2D1-0C3880D3AC4FQ27314587-F251F5CA-0126-4802-9809-7F70C5D8BB65Q27665609-A06989E1-87E8-4992-9A5D-4CB193829ED8Q28247101-78B1F98F-6CB8-4F2D-BD2D-D17D279AF7F2Q28748625-E5A4C825-4E8F-450F-96EB-1BEA2E3009B2Q30417586-6D38C8FC-1BD0-4338-B3C5-C561010F4656Q30444900-17884BAA-B903-4E0C-84A1-067A6EBD3936Q30837074-F76BED0F-4F5E-451A-A335-E8D4599F995FQ30960052-EB5001A2-1BED-4EA2-A0A2-F5543B769B40Q33412801-2A008230-040A-4BBC-B0B9-2EEEFC4C7AB8Q33775276-733E7B59-1EA0-4C0C-83FD-4CD8082E6ED6Q33807755-12D279DC-17A6-44FD-9D54-14BB4A1257F7Q33812633-E42350AC-7584-4A95-8FD7-BAF10D6EC708Q33841304-6482D244-BB48-4E1A-8B1D-A2D396C2F996Q33923975-E1E1DA35-5461-4921-8F70-3D22814BF6BFQ33926857-52B7071E-5D62-4993-B3DA-12EBD13A9301Q34097292-B5617C9D-8683-4CB6-B6FD-8B8F554E2EECQ34246678-B4A43935-D2B9-4B08-BC10-E07ACDD31332Q34455658-F17ACD4E-C23B-4CF8-A79B-36EE72AA18E0Q34468628-D4319DE8-FB22-4F93-B59D-75397251DD2AQ34768288-1BE2CB7C-7192-4937-9D14-572A2C51CE93Q35050772-C0548D53-A6F8-4F14-9A15-E0ADA25E0A07Q35125726-DF162EBA-CFE2-453E-999D-AFFCE2D4AFD0Q35169011-514F8827-C428-42FC-BE1C-656F762A87BEQ35609161-EB7549A3-743D-447E-8AB4-35A222C1E992Q35655672-3C664A00-E6E6-4717-B7E7-62383DDB47A1Q35688238-5E10C5CA-9078-43E1-B933-B839FFC659CAQ35848403-6B332A48-E886-4B24-BB40-E3DFCECB4401Q35907111-B907B522-75E4-499A-BDDA-A9A969A83B3AQ35946793-BED3556F-4E0A-42C3-900B-E779C8DAB47CQ36126605-89AC477B-A7F9-49C6-9197-514B08BF5AE9Q36196359-B1F3B22C-6718-4D05-A999-411A7EADD80FQ36749303-A4BB1B7A-47C2-4C69-8212-52AEF3B3E674Q37035110-A02B546D-C5B7-4436-8C5B-001FD8EAB041Q37159547-FAA9642C-8BA3-4AAE-9162-D976FAD00959Q37340600-54A0BA53-42EA-4FDE-AF6E-2BFB13605BB4Q37344283-2B990FC2-CB2E-49E2-BDA2-7A4A2F7BC020
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The camptothecins.
@ast
The camptothecins.
@en
type
label
The camptothecins.
@ast
The camptothecins.
@en
prefLabel
The camptothecins.
@ast
The camptothecins.
@en
P1433
P1476
The camptothecins
@en
P2093
Joseph F Pizzolato
P304
P356
10.1016/S0140-6736(03)13780-4
P407
P577
2003-06-01T00:00:00Z